A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity
Retinopathy of Prematurity
About this trial
This is an interventional treatment trial for Retinopathy of Prematurity
Eligibility Criteria
Inclusion Criteria: Infants with Type 1 ROP according to ETROP study which is defined as: Zone I ROP with plus disease Zone I, stage 3 ROP without plus disease Zone II, stage 2 or 3 ROP with plus disease Exclusion Criteria: Eyes with previous intravitreal injection Eyes with previous laser therapy Eyes with any other intraocular pathology other than ROP (congenital cataract, congenital glaucoma, any retinal pathology other than ROP)
Sites / Locations
- Faculty of Medicine Cairo University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Group A recieved 0.3125mg intravitreal bevacizumab in both eyes
Group B received 0.625mg intravitreal bevacizumab in both eyes
9 infants in group A with type 1 ROP , received 0.3125mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .
10 infants in group B with type 1 ROP , received 0.625mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .